Found 64 matching trials
SGLT2-Inhibitors for Sleep Apnea in Heart Failure
PHASE2Heart Failure is a disease involving many different aspects of the human bo...
Location
Vivian and Seymour Milstein Family Heart Center
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
PHASE2Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage...
Location
Multiple Locations
Effect of Dapagliflozine on Systemic and Renal Endothelial Function
PHASE4This is a phase 4, single center, randomized, open-labeled, cross-over desi...
Location
Boramae medical center
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
EARLY_PHASE1This study aims to understand the heart and blood sugar health benefits of ...
Location
Vanderbilt University Medical Center
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008
PHASE1To evaluate the safety and pharmacokinetic characteristics after the admini...
Location
Bundang CHA university global clinical trials center Institutional Review Board
Empaglifozin in Early Diabetic Kidney Disease
PHASE3Background:
Diabetes is common among American Indian people and diabetic k...
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
PHASE1Background:
The drug empagliflozin treats diabetes. It lowers blood sugar ...
Location
National Institute on Aging, Clinical Research Unit
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
PHASE4The study titled "Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl ...
Location
BIRDEM General Hospital
Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients
N/AThe aim of the study is to evaluate the benefits, documented in experimenta...
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
PHASE3This was a parallel-group treatment, Phase 3, randomized, 2-arm study that ...
Location
Investigational Site Number : 1560008